US20110118133A1 - Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication - Google Patents
Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication Download PDFInfo
- Publication number
- US20110118133A1 US20110118133A1 US13/015,068 US201113015068A US2011118133A1 US 20110118133 A1 US20110118133 A1 US 20110118133A1 US 201113015068 A US201113015068 A US 201113015068A US 2011118133 A1 US2011118133 A1 US 2011118133A1
- Authority
- US
- United States
- Prior art keywords
- polymorphism
- seq
- intron
- gene
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 46
- 238000011282 treatment Methods 0.000 title description 18
- 239000000935 antidepressant agent Substances 0.000 title description 10
- 229940005513 antidepressants Drugs 0.000 title description 10
- 230000001430 anti-depressive effect Effects 0.000 title description 7
- 229940079593 drug Drugs 0.000 title description 5
- 239000003814 drug Substances 0.000 title description 5
- 230000002411 adverse Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 44
- 206010042458 Suicidal ideation Diseases 0.000 claims abstract description 19
- 102000018899 Glutamate Receptors Human genes 0.000 claims abstract description 8
- 108010027915 Glutamate Receptors Proteins 0.000 claims abstract description 8
- 230000001057 ionotropic effect Effects 0.000 claims abstract description 8
- 238000012216 screening Methods 0.000 claims abstract description 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 6
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 claims abstract description 5
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 claims abstract description 5
- 108010025843 glutamine receptor Proteins 0.000 claims abstract description 4
- 108700028369 Alleles Proteins 0.000 claims description 16
- 102100034934 Papilin Human genes 0.000 claims description 15
- 101710142044 Papilin Proteins 0.000 claims description 15
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 14
- 102100030652 Glutamate receptor 1 Human genes 0.000 claims description 10
- 101001010445 Homo sapiens Glutamate receptor 1 Proteins 0.000 claims description 10
- 102000005962 receptors Human genes 0.000 claims description 9
- 108020003175 receptors Proteins 0.000 claims description 9
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 claims description 7
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 claims description 7
- 102000017678 HTR3B Human genes 0.000 claims description 7
- 101000964058 Homo sapiens 5-hydroxytryptamine receptor 3B Proteins 0.000 claims description 7
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 claims description 7
- 101001125242 Homo sapiens Glutamate receptor ionotropic, NMDA 2A Proteins 0.000 claims description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 238000000123 temperature gradient gel electrophoresis Methods 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 4
- 238000009396 hybridization Methods 0.000 claims description 4
- 229940076279 serotonin Drugs 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 108091027305 Heteroduplex Proteins 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 108010063738 Interleukins Proteins 0.000 claims description 3
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 claims description 3
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 claims description 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 3
- 108091000080 Phosphotransferase Proteins 0.000 claims description 3
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 claims description 3
- 238000004949 mass spectrometry Methods 0.000 claims description 3
- 238000010208 microarray analysis Methods 0.000 claims description 3
- 230000000508 neurotrophic effect Effects 0.000 claims description 3
- 102000020233 phosphotransferase Human genes 0.000 claims description 3
- 108010002164 tyrosine receptor Proteins 0.000 claims description 3
- 239000003550 marker Substances 0.000 description 42
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 28
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 24
- 238000012360 testing method Methods 0.000 description 21
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 20
- 210000000349 chromosome Anatomy 0.000 description 17
- 229930024421 Adenine Natural products 0.000 description 16
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 16
- 229960000643 adenine Drugs 0.000 description 16
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 14
- 229960001653 citalopram Drugs 0.000 description 14
- 229940104302 cytosine Drugs 0.000 description 14
- 229940113082 thymine Drugs 0.000 description 12
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 11
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 11
- 206010010144 Completed suicide Diseases 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 208000024714 major depressive disease Diseases 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000007477 logistic regression Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 101150006929 GRIK2 gene Proteins 0.000 description 2
- 102100030669 Glutamate receptor 3 Human genes 0.000 description 2
- 102100022758 Glutamate receptor ionotropic, kainate 2 Human genes 0.000 description 2
- 101150069432 Gria3 gene Proteins 0.000 description 2
- 101001010434 Homo sapiens Glutamate receptor 3 Proteins 0.000 description 2
- 238000001207 Hosmer–Lemeshow test Methods 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 238000003657 Likelihood-ratio test Methods 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- 101150068134 PAPLN gene Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- -1 tricyclics Substances 0.000 description 2
- 102000003678 AMPA Receptors Human genes 0.000 description 1
- 108090000078 AMPA Receptors Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 101100448899 Arabidopsis thaliana GLR3.5 gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101150049131 Gria1 gene Proteins 0.000 description 1
- 101150078247 HTR3B gene Proteins 0.000 description 1
- 101000903346 Homo sapiens Glutamate receptor ionotropic, kainate 2 Proteins 0.000 description 1
- 206010022035 Initial insomnia Diseases 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 101150056950 Ntrk2 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000001358 Pearson's chi-squared test Methods 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 101150002245 grin2a gene Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- Depression is a disease that affects a large proportion of the population and is a result of multiple factors. According to the World Health Organization (WHO), depression ranks among the ten leading causes of disability and will become the second-largest cause of the global health burden by 2020. An estimated 121 million people worldwide suffer from a depressive disorder for which they require treatment. It is estimated that 5.8% of all men and 9.5% of all women will suffer from a depressive disorder in any given year and that 17% of all men and women will suffer from a depressive disorder at some point in their lives.
- WHO World Health Organization
- SSRIs selective serotonin reuptake inhibitors
- MAOIs monoamine oxidase inhibitors
- the invention provides a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof.
- GRIA3 glutamate receptor ionotropic AMPA 3
- TESI biological basis for TESI following treatment with antidepressants, such as SSRIs, previously was unknown.
- antidepressants such as SSRIs
- the inventors have determined that specific genetic markers can shed light on the causes of TESI and help to identify individuals that are at high-risk for TESI and that can benefit from closer monitoring, alternative treatments, and/or specialty care.
- the inventors utilized the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, which is a large prospective treatment trial for major depression to test whether specific genetic markers could predict TESI in patients treated with the selective serotonin reuptake inhibitor (SSRI) citalopram.
- STAR*D Sequenced Treatment Alternatives to Relieve Depression
- the inventors identified genetic markers that identify patients at high risk of developing suicidal thoughts during treatment with the SSRI citalopram.
- the markers reside in the genes glutamine receptor, ionotropic, kainate 2 (GRIK2) and glutamate receptor ionotropic AMPA 3 (GRIA3).
- GRIK2 and GRIA3 encode receptors for the excitatory neurotransmitter glutamate.
- Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes with multiple subunits, each possessing transmembrane regions, and all arranged to form a ligand-gated ion channel. The classification of glutamate receptors is based on their activation by different pharmacologic agonists.
- GRIK2 encodes a subunit of a kainate glutamate receptor. GRIK2 also is known as EAA4, GLR6, GLUR6, GLuR-6, and G1uR-6. GRIK2 is located on chromosome 6g16.3-q21. GRIK2 is identified by GenBank Accession Numbers BC037954 and AAH37954, as well as IMAGE clone 5728492.
- GRIA3 belongs to a family of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. Alternative splicing results in several different isoforms which may vary in their signal transduction properties. GRIA3 also is known as GLUR-K3, GLUR3, GLURC, G1uR-3, G1uR-K3, and gluR-C. GRIA3 is located on chromosome Xq25-q26. GRIA3 is identified by GenBank Accession Numbers BC032004 and AAH32004, as well as IMAGE clone 4753474.
- the invention is directed to a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients that is associated with an increased risk of TESI, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of GRIK2, GRIA3, and combinations thereof.
- TESI refers to the appearance of suicidal thoughts and/or behavior following treatment, such as treatment with SSRIs.
- suicidal thoughts and behavior include, but are not limited to, the following: feeling that life is empty and/or wondering if life is worth living; thinking of suicide or death several times a week for several minutes; thinking of suicide or death several times a day in some detail; making specific plans for suicide; and attempting or succeeding in taking one's life.
- a patient refers to an individual awaiting or under medical care and treatment, such as treatment for depression. While the inventive methods are designed for human patients (e.g., male and female human patients), such methods are applicable to any suitable individual, which includes, but is not limited to, a mammal, such as a mouse, rat, rabbit, hamster, guinea pig, cat, dog, goat, cow, horse, pig, and simian.
- a mammal such as a mouse, rat, rabbit, hamster, guinea pig, cat, dog, goat, cow, horse, pig, and simian.
- the sample of genetic material can be obtained from the patient by any suitable manner.
- the sample can be isolated from a source including saliva, buccal cells, hair roots, blood, cord blood, amniotic fluid, interstitial fluid, peritoneal fluid, chorionic villus, semen, or other suitable cell or tissue sample. Methods for isolating genomic DNA from various sources is well-known in the art.
- a polymorphism refers to one of multiple alleles of a gene.
- the polymorphism is a single nucleotide polymorphism (SNP).
- the polymorphism that is associated with an increased risk of TESI can be detected by any suitable manner known in the art.
- the polymorphism can be detected by techniques, such as allele specific hybridization, allele specific oligonucleotide ligation, primer extension, minisequencing, mass spectroscopy, heteroduplex analysis, single strand conformational polymorphism (SSCP), denaturing gradient gel electrophoresis (DGGE), oligonucleotide microarray analysis, temperature gradient gel electrophoresis (TGGE), and combinations thereof.
- the polymorphism that is associated with an increased risk of TESI in the GRIK2 gene typically is within intron 1 of GRIK2 (GenBank Accession Number NM — 021956).
- intron 1 of GRIK2 typically comprises SEQ ID NO: 1, which contains a cytosine at position 201, rather than adenine (which is present in the GRIK2 intron 1 that is not associated with an increased risk of TESI).
- This adenine/cytosine SNP is associated with marker rs2518224 at chromosome 6:102013370.
- the polymorphism that is associated with an increased risk of TESI in the GRIA3 gene typically is within intron 3 of GRIA3 (GenBank Accession Number NM — 000828).
- intron 3 of GRIA3 typically comprises SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 13.
- SEQ ID NO: 2 contains a thymine at position 201, rather than adenine (which is present in the GRIA3 intron 3 that is not associated with an increased risk of TESI).
- This adenine/thymine SNP is associated with marker rs6608067 at chromosome X:122151011.
- SEQ ID NO: 3 contains a guanine at position 201, rather than adenine (which is present in the GRIA3 gene that is not associated with an increased risk of TEST). This adenine/guanine SNP is associated with marker rs4825476 at chromosome X:122167014.
- SEQ ID NO: 13 contains a thymine at position 201, rather than cytosine (which is present in the GRIA3 intron 3 that is not associated with an increased risk of TESI). This cytosine/thymine SNP is associated with marker rs5911588 at chromosome X:122286074.
- the invention also comprises assaying for the presence of a genotype that is associated with an increased risk of TESI, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of: glutamate receptor, ionotropic, N-methyl D-aspartate (GRIN) 2A; neurotrophic tyrosine receptor kinase (NTRK) 2; 5-hydroxytryptamine (serotonin) receptor (HTR) 3B; GRIA1; papilin (PAPLN); interleukin 28 receptor alpha (IL28RA); and combinations thereof.
- GRIN glutamate receptor, ionotropic, N-methyl D-aspartate
- NTRK neurotrophic tyrosine receptor kinase
- HTR 5-hydroxytryptamine receptor
- PAPLN interleukin 28 receptor alpha
- IL28RA interleukin 28 receptor alpha
- the polymorphism that is associated with an increased risk of TESI in GRIN2A typically is within intron 3 of GRIN2A (GenBank Accession Number NM000833).
- intron 3 of GRIN2A typically comprises SEQ ID NO: 4, which contains a cytosine at position 201, rather than adenine (which is present in the GRIN2A gene that is not associated with an increased risk of TESI).
- This thymine/guanine SNP (opposite strand) is associated with marker rs3104703 at chromosome 16:9972637.
- intron 14 of NTRK2 typically comprises SEQ ID NO: 5, which contains a guanine at position 201, rather than adenine (which is present in the NTRK2 gene that is not associated with an increased risk of TESI).
- This cytosine/thymine SNP is associated with marker rs1573219 at chromosome 9:84617176.
- the polymorphism that is associated with an increased risk of TESI in HTR3B typically is within intron 6 of HTR3B (GenBank Accession Number NM — 006028).
- intron 6 (boundary) of HTR3B typically comprises SEQ ID NO: 6, which contains a guanine at position 201, rather than adenine (which is present in the HTR3B gene that is not associated with an increased risk of TESI).
- This adenine/guanine SNP (opposite strand) is associated with marker rs2276307 at chromosome 11:113309097.
- the polymorphism that is associated with an increased risk of TESI in GRIA1 typically is within intron 5 of GRIA1 (GenBank Accession Number NM — 000827).
- intron 5 of GRIA1 typically comprises SEQ ID NO: 7, which contains a cytosine at position 201, rather than adenine (which is present in the GRIA1 gene that is not associated with an increased risk of TESI).
- This adenine/cytosine SNP is associated with marker rs4958672 at chromosome 5:153028245.
- the polymorphism that is associated with an increased risk of TESI in PAPLN typically is within intron 13 of PAPLN (GenBank Accession Number NM — 173462).
- intron 13 (boundary) of PAPLN typically comprises SEQ ID NO: 8, which contains a guanine at position 201, rather than adenine (which is present in the PAPLN gene that is not associated with an increased risk of TESI).
- This adenine/guanine SNP is associated with marker rs2293796 at chromosome 14:72790915.
- intron 13 (boundary) of PAPLN can comprise SEQ ID NO: 9, which contains a thymine at position 201, rather than a cytosine (which is present in the PAPLN gene that is not associated with an increased risk of TESI).
- This cytosine/thymine SNP is associated with marker rs11628713 at chromosome 14:72791528.
- exon 7 of IL28RA typically comprises SEQ ID NO: 10, which contains a guanine at position 201, rather than adenine (which is present in the IL28RA gene that is not associated with an increased risk of TESI).
- SEQ ID NO: 10 which contains a guanine at position 201, rather than adenine (which is present in the IL28RA gene that is not associated with an increased risk of TESI).
- This adenine/guanine SNP is associated with marker rs10903034 at chromosome 1:24226211.
- exon 7 of IL28RA can comprise SEQ ID NO: 11, which contains a thymine at position 201, rather than cytosine (which is present in the IL28RA gene that is not associated with an increased risk of TESI).
- This cytosine/thymine SNP is associated with marker rs11249006 at chromosome 1:24227780.
- intron 4 of IL28RA typically comprises SEQ ID NO: 12, which contains thymine at position 201, rather than cytosine (which is present in the IL28RA gene that is not associated with an increased risk of TESI).
- This cytosine/thymine SNP is associated with marker rs1416834 at chromosome 1:24231966.
- Sensitivity is the probability that a symptom is present (or the screening test is positive) when a patient has a disorder.
- the sensitivity of the polymorphism associated with TESI in the inventive method can be any suitable sensitivity.
- the sensitivity is about 0.5 or higher (e.g., about 0.55, about 0.6, about 0.65, about 0.7, about 0.75, about 0.8, about 0.85, about 0.9, about 0.95, and ranges thereof).
- Specificity is the probability that a symptom is not present (or the screening test is negative) when a patient does not have a disorder.
- the specificity of the polymorphism associated with TESI in the inventive method can be any suitable specificity.
- the specificity is about 0.5 or higher (e.g., about 0.55, about 0.6, about 0.65, about 0.7, about 0.75, about 0.8, about 0.85, about 0.9, about 0.95, and ranges thereof).
- Positive predictive value is the probability that a patient has a disorder given a positive test result.
- the positive predictive value of the polymorphism associated with TESI in the inventive method can be any suitable value.
- the positive predictive value is about 0.05 or higher (e.g., about 0.1, about 0.2, about 0.25, about 0.3, about 0.4, about 0.5, about 0.55, about 0.6, about 0.65, about 0.7, about 0.75, about 0.8, about 0.85, about 0.9, about 0.95, and ranges thereof).
- Negative predictive value is the probability that a patient has the disorder given a negative test result.
- the negative predictive value of the polymorphism associated with TESI in the inventive method can be any suitable value.
- the negative predictive value is about 0.5 or higher (e.g., about 0.55, about 0.6, about 0.65, about 0.7, about 0.75, about 0.8, about 0.85, about 0.9, about 0.95, and ranges thereof).
- the invention also contains a kit comprising reagents suitable for applying the methods of the invention.
- the kit provides the necessary materials for identifying the polymorphism packaged into a suitable container.
- the kit contains a reagent that identifies a polymorphism in the selected gene that is associated with a selected trait, such as TESI.
- the reagent is a set of primers or a PCR set (a set of primers, DNA polymerase, and 4 nucleoside triphosphates) that hybridizes with the gene or a fragment thereof.
- the kit also can include other reagents for detecting or measuring the detectable entity and/or a control. Other reagents used for hybridization, prehybridization, DNA extraction, visualization, and the like also can be included.
- This example demonstrates that genetic markers can be used to identify individuals with a major depressive disorder who develop treatment-emergent suicidal ideation (TESI) when exposed to a selective-serotonin reuptake inhibitor (SSRI), such as citalopram.
- TESI treatment-emergent suicidal ideation
- SSRI selective-serotonin reuptake inhibitor
- Genes were selected to sample five broad signaling pathways of potential importance in antidepressant effects: serotonin (20 genes), glutamate (16 genes), dopamine (3 genes), norepinephrine (4 genes), and neurotrophins (4 genes), as well as selected genes in other pathways (21 genes). All probands with TESI and a subset of probands without TESI were also screened with the Illumina 109K Exon-Centric chip, which measures the genotype of a DNA sample at each of 109,000 SNPs in and near most known human genes.
- the 16-item Quick Inventory of Depressive Symptomatology—Self-report (QIDS-SR 16 ) was used as a measure of symptom severity (see Rush et al., Int. J. Methods Psychiatr. Res. , 9:45-59 (2000): Rush et al., Biol. Psychiatry , 54 (5): 573-583 (2003); Trivedi et al., Psychol. Med. , 34 (1):73-82 (2004); Rush et al., Neuropsychompharmacology , 30 (2):405-416 (2005); and Rush et al., Biol.
- Allele and genotype frequencies were compared between the 120 participants who developed TESI and those who did not develop TESI. Allele-wise tests are most powerful for alleles that confer risk in a co-dominant or dominant fashion, while genotype-wise tests are more powerful when a recessive model applies. Allele-wise comparisons were performed with Cocaphase in the UNPHASED package (see Dudbridge et al., Am. J. Hum. Genet. , 75 (3):424-435 (2004)), which estimates a likelihood-based test of association under the null hypothesis of all odds ratios (ORs) being equal to one. Genotype-wise comparisons were carried out using a Pearson Chi-square test on a 2 ⁇ 3 contingency table.
- Tests of association included a logistic regression model calculated with SAS 9.1.3 Enterprise Guide 3.0 (SAS Institute, Cary, N.C.), with a nominal dependent variable for TESI.
- X-linked markers were separately analyzed in males and females.
- Single marker tests were carried out under co-dominant, dominant, and recessive models.
- Models were compared by the Likelihood Ratio Test (LRT). The best-fitting model was used for the multi-marker analyses.
- the reference model was based on the SNPs with the largest identified ORs in the single marker models. The remaining covariates were added in a step-wise fashion in descending order of OR.
- the 2 log-likelihood ( ⁇ 2Log L) was used to assess the improvement of fit as each variable was removed from the model.
- the Hosmer-Lemeshow test was used to test for final model fit.
- markers Two markers were significantly associated with TESI.
- Table 1 includes demographic and clinical data for the 120 participants and the 1742 controls.
- Tables 2 and 3 demonstrate logistic regression models with stepwise selection for the two markers, wherein race was forced into each model.
- the c index for this model is 0.64.
- the c index for this model is 0.73.
- the clinical parameters for markers 157 and 239 are reported in Table 4.
- the high-risk genotype of marker 157 correlates with a SNP in intron 1 of GRIK2 (e.g., SEQ ID NO: 1).
- the high-risk alleles of marker 239 contain a SNP in intron 3 of GRIA3 (e.g., SEQ ID NOs: 2 and 3).
- CI 95% Confidence Interval
- the most sensitive test (57%) required the presence of one or more high-risk alleles of marker 239 only.
- the combined impact of both markers on TESI risk appears to be at least additive, but sample size precludes any precise estimates of the mode of interaction.
- markers can help identify patients at high risk for TESI. Such patients will benefit from closer monitoring, alternative treatments, and/or specialty care. Such testing can allay the concern that has led regulatory agencies to issue warnings that contribute to a decrease in antidepressant prescriptions for patients who could benefit from them. Rather than broad warnings that can inappropriately affect antidepressant prescribing practices, identification of these markers indicates that narrower warnings could be appropriate that better capture the heterogeneous nature of TESI risk in those patients treated with antidepressants.
- markers were identified that correlate with an increased risk of TESI. These markers were identified in the following genes: GRIN2A, NTRK2, HTR3B, GRIA1, and PAPLN. SNPs in intron 3 of GRIN2A (e.g., SEQ ID NO: 4), intron 14 of NTRK2 (e.g., SEQ ID NO: 5), intron 16 of HTR3B (e.g., SEQ ID NO: 6), intron 5 of GRIA1 (SEQ ID NO: 7), and intron 13 of PAPLN (e.g., SEQ ID NOs: 8 or 9) were associated with increased risk of TESI in those treated with citalopram.
- SEQ ID NOs: 4 SNPs in intron 3 of GRIN2A (e.g., SEQ ID NO: 4), intron 14 of NTRK2 (e.g., SEQ ID NO: 5), intron 16 of HTR3B (e.g., SEQ ID NO: 6), intron 5 of GRIA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising: (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof.
Description
- This patent application claims the benefit of U.S. Provisional Patent Application No. 60/854,978, filed Oct. 27, 2006, and is incorporated by reference herein.
- Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: One 8,236 Byte ASCII (Text) file named “702157.ST25.TXT,” created on Oct. 25, 2007.
- Depression is a disease that affects a large proportion of the population and is a result of multiple factors. According to the World Health Organization (WHO), depression ranks among the ten leading causes of disability and will become the second-largest cause of the global health burden by 2020. An estimated 121 million people worldwide suffer from a depressive disorder for which they require treatment. It is estimated that 5.8% of all men and 9.5% of all women will suffer from a depressive disorder in any given year and that 17% of all men and women will suffer from a depressive disorder at some point in their lives.
- Several types of antidepressant medications are used to treat depressive disorders, such as selective serotonin reuptake inhibitors (SSRIs), tricyclics, and monoamine oxidase inhibitors (MAOIs). The SSRIs and other medications that affect neurotransmitters, such as dopamine and norepinephrine, generally have fewer side effects than tricyclics. However, studies report a potential link between antidepressant use and the emergence of suicidal tendencies. According to some studies suicidal ideation (SI) is an uncommon but potentially dangerous phenomenon that can emerge during antidepressant treatment. Although there is no clear understanding of the basis for the observed linkage, the Food and Drug Administration (FDA) issued a black box warning regarding the potential risk of worsening depression and/or emergence of suicidality (i.e., development of suicidal thoughts or behavior) in both adult and pediatric patients taking several antidepressants.
- In view of the FDA's warning, there has been increasing hesitation by physicians to prescribe antidepressants, particularly to children and adolescents. The need exists for a method to identify individuals at risk for developing these dangerous side effects. The invention provides such a method that could provide information about a patient's susceptibility for treatment-emergent suicidal ideation (TESI). These and other objects and advantages of the invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.
- The invention provides a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof.
- The biological basis for TESI following treatment with antidepressants, such as SSRIs, previously was unknown. The inventors have determined that specific genetic markers can shed light on the causes of TESI and help to identify individuals that are at high-risk for TESI and that can benefit from closer monitoring, alternative treatments, and/or specialty care.
- The inventors utilized the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, which is a large prospective treatment trial for major depression to test whether specific genetic markers could predict TESI in patients treated with the selective serotonin reuptake inhibitor (SSRI) citalopram.
- The inventors identified genetic markers that identify patients at high risk of developing suicidal thoughts during treatment with the SSRI citalopram. The markers reside in the genes glutamine receptor, ionotropic, kainate 2 (GRIK2) and glutamate receptor ionotropic AMPA 3 (GRIA3).
- GRIK2 and GRIA3 encode receptors for the excitatory neurotransmitter glutamate. Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes with multiple subunits, each possessing transmembrane regions, and all arranged to form a ligand-gated ion channel. The classification of glutamate receptors is based on their activation by different pharmacologic agonists.
- GRIK2 encodes a subunit of a kainate glutamate receptor. GRIK2 also is known as EAA4, GLR6, GLUR6, GLuR-6, and G1uR-6. GRIK2 is located on chromosome 6g16.3-q21. GRIK2 is identified by GenBank Accession Numbers BC037954 and AAH37954, as well as IMAGE clone 5728492.
- GRIA3 belongs to a family of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. Alternative splicing results in several different isoforms which may vary in their signal transduction properties. GRIA3 also is known as GLUR-K3, GLUR3, GLURC, G1uR-3, G1uR-K3, and gluR-C. GRIA3 is located on chromosome Xq25-q26. GRIA3 is identified by GenBank Accession Numbers BC032004 and AAH32004, as well as IMAGE clone 4753474.
- The invention is directed to a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients that is associated with an increased risk of TESI, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of GRIK2, GRIA3, and combinations thereof.
- TESI refers to the appearance of suicidal thoughts and/or behavior following treatment, such as treatment with SSRIs. For example, suicidal thoughts and behavior include, but are not limited to, the following: feeling that life is empty and/or wondering if life is worth living; thinking of suicide or death several times a week for several minutes; thinking of suicide or death several times a day in some detail; making specific plans for suicide; and attempting or succeeding in taking one's life.
- A patient refers to an individual awaiting or under medical care and treatment, such as treatment for depression. While the inventive methods are designed for human patients (e.g., male and female human patients), such methods are applicable to any suitable individual, which includes, but is not limited to, a mammal, such as a mouse, rat, rabbit, hamster, guinea pig, cat, dog, goat, cow, horse, pig, and simian.
- The sample of genetic material can be obtained from the patient by any suitable manner. The sample can be isolated from a source including saliva, buccal cells, hair roots, blood, cord blood, amniotic fluid, interstitial fluid, peritoneal fluid, chorionic villus, semen, or other suitable cell or tissue sample. Methods for isolating genomic DNA from various sources is well-known in the art.
- A polymorphism refers to one of multiple alleles of a gene. Preferably, the polymorphism is a single nucleotide polymorphism (SNP).
- The polymorphism that is associated with an increased risk of TESI can be detected by any suitable manner known in the art. For example, the polymorphism can be detected by techniques, such as allele specific hybridization, allele specific oligonucleotide ligation, primer extension, minisequencing, mass spectroscopy, heteroduplex analysis, single strand conformational polymorphism (SSCP), denaturing gradient gel electrophoresis (DGGE), oligonucleotide microarray analysis, temperature gradient gel electrophoresis (TGGE), and combinations thereof.
- The polymorphism that is associated with an increased risk of TESI in the GRIK2 gene typically is within intron 1 of GRIK2 (GenBank Accession Number NM—021956). In such a situation, intron 1 of GRIK2 typically comprises SEQ ID NO: 1, which contains a cytosine at position 201, rather than adenine (which is present in the GRIK2 intron 1 that is not associated with an increased risk of TESI). This adenine/cytosine SNP is associated with marker rs2518224 at chromosome 6:102013370.
- The polymorphism that is associated with an increased risk of TESI in the GRIA3 gene typically is within intron 3 of GRIA3 (GenBank Accession Number NM—000828). In such a situation, intron 3 of GRIA3 typically comprises SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 13. SEQ ID NO: 2 contains a thymine at position 201, rather than adenine (which is present in the GRIA3 intron 3 that is not associated with an increased risk of TESI). This adenine/thymine SNP is associated with marker rs6608067 at chromosome X:122151011. SEQ ID NO: 3 contains a guanine at position 201, rather than adenine (which is present in the GRIA3 gene that is not associated with an increased risk of TEST). This adenine/guanine SNP is associated with marker rs4825476 at chromosome X:122167014. SEQ ID NO: 13 contains a thymine at position 201, rather than cytosine (which is present in the GRIA3 intron 3 that is not associated with an increased risk of TESI). This cytosine/thymine SNP is associated with marker rs5911588 at chromosome X:122286074.
- The invention also comprises assaying for the presence of a genotype that is associated with an increased risk of TESI, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of: glutamate receptor, ionotropic, N-methyl D-aspartate (GRIN) 2A; neurotrophic tyrosine receptor kinase (NTRK) 2; 5-hydroxytryptamine (serotonin) receptor (HTR) 3B; GRIA1; papilin (PAPLN); interleukin 28 receptor alpha (IL28RA); and combinations thereof. Certain polymorphisms in these genes correlate with an increased risk of developing suicidal thoughts during treatment with the SSRI citalopram.
- The polymorphism that is associated with an increased risk of TESI in GRIN2A typically is within intron 3 of GRIN2A (GenBank Accession Number NM000833). In such a situation, intron 3 of GRIN2A typically comprises SEQ ID NO: 4, which contains a cytosine at position 201, rather than adenine (which is present in the GRIN2A gene that is not associated with an increased risk of TESI). This thymine/guanine SNP (opposite strand) is associated with marker rs3104703 at chromosome 16:9972637.
- The polymorphism that is associated with an increased risk of TEST in NTRK2 typically is within intron 14 of NTRK2 (GenBank Accession Number NM—001018064). In such a situation, intron 14 of NTRK2 typically comprises SEQ ID NO: 5, which contains a guanine at position 201, rather than adenine (which is present in the NTRK2 gene that is not associated with an increased risk of TESI). This cytosine/thymine SNP (opposite strand) is associated with marker rs1573219 at chromosome 9:84617176.
- The polymorphism that is associated with an increased risk of TESI in HTR3B typically is within intron 6 of HTR3B (GenBank Accession Number NM—006028). In such a situation, intron 6 (boundary) of HTR3B typically comprises SEQ ID NO: 6, which contains a guanine at position 201, rather than adenine (which is present in the HTR3B gene that is not associated with an increased risk of TESI). This adenine/guanine SNP (opposite strand) is associated with marker rs2276307 at chromosome 11:113309097.
- The polymorphism that is associated with an increased risk of TESI in GRIA1 typically is within intron 5 of GRIA1 (GenBank Accession Number NM—000827). In such a situation, intron 5 of GRIA1 typically comprises SEQ ID NO: 7, which contains a cytosine at position 201, rather than adenine (which is present in the GRIA1 gene that is not associated with an increased risk of TESI). This adenine/cytosine SNP is associated with marker rs4958672 at chromosome 5:153028245.
- The polymorphism that is associated with an increased risk of TESI in PAPLN typically is within intron 13 of PAPLN (GenBank Accession Number NM—173462). In such a situation, intron 13 (boundary) of PAPLN typically comprises SEQ ID NO: 8, which contains a guanine at position 201, rather than adenine (which is present in the PAPLN gene that is not associated with an increased risk of TESI). This adenine/guanine SNP is associated with marker rs2293796 at chromosome 14:72790915. Similarly, in such a situation, intron 13 (boundary) of PAPLN can comprise SEQ ID NO: 9, which contains a thymine at position 201, rather than a cytosine (which is present in the PAPLN gene that is not associated with an increased risk of TESI). This cytosine/thymine SNP is associated with marker rs11628713 at chromosome 14:72791528.
- The polymorphism that is associated with an increased risk of TESI in IL28RA typically is within exon 7 or intron 4 of IL28RA (GenBank Accession Number NM—170743). In such a situation, exon 7 of IL28RA typically comprises SEQ ID NO: 10, which contains a guanine at position 201, rather than adenine (which is present in the IL28RA gene that is not associated with an increased risk of TESI). This adenine/guanine SNP is associated with marker rs10903034 at chromosome 1:24226211. Similarly, exon 7 of IL28RA can comprise SEQ ID NO: 11, which contains a thymine at position 201, rather than cytosine (which is present in the IL28RA gene that is not associated with an increased risk of TESI). This cytosine/thymine SNP is associated with marker rs11249006 at chromosome 1:24227780. Similarly, in such a situation, intron 4 of IL28RA typically comprises SEQ ID NO: 12, which contains thymine at position 201, rather than cytosine (which is present in the IL28RA gene that is not associated with an increased risk of TESI). This cytosine/thymine SNP is associated with marker rs1416834 at chromosome 1:24231966.
- Sensitivity is the probability that a symptom is present (or the screening test is positive) when a patient has a disorder. The sensitivity of the polymorphism associated with TESI in the inventive method can be any suitable sensitivity. Preferably, the sensitivity is about 0.5 or higher (e.g., about 0.55, about 0.6, about 0.65, about 0.7, about 0.75, about 0.8, about 0.85, about 0.9, about 0.95, and ranges thereof).
- Specificity is the probability that a symptom is not present (or the screening test is negative) when a patient does not have a disorder. The specificity of the polymorphism associated with TESI in the inventive method can be any suitable specificity. Preferably, the specificity is about 0.5 or higher (e.g., about 0.55, about 0.6, about 0.65, about 0.7, about 0.75, about 0.8, about 0.85, about 0.9, about 0.95, and ranges thereof).
- Positive predictive value is the probability that a patient has a disorder given a positive test result. The positive predictive value of the polymorphism associated with TESI in the inventive method can be any suitable value. Preferably, the positive predictive value is about 0.05 or higher (e.g., about 0.1, about 0.2, about 0.25, about 0.3, about 0.4, about 0.5, about 0.55, about 0.6, about 0.65, about 0.7, about 0.75, about 0.8, about 0.85, about 0.9, about 0.95, and ranges thereof).
- Negative predictive value is the probability that a patient has the disorder given a negative test result. The negative predictive value of the polymorphism associated with TESI in the inventive method can be any suitable value. Preferably, the negative predictive value is about 0.5 or higher (e.g., about 0.55, about 0.6, about 0.65, about 0.7, about 0.75, about 0.8, about 0.85, about 0.9, about 0.95, and ranges thereof).
- The invention also contains a kit comprising reagents suitable for applying the methods of the invention. The kit provides the necessary materials for identifying the polymorphism packaged into a suitable container. At a minimum, the kit contains a reagent that identifies a polymorphism in the selected gene that is associated with a selected trait, such as TESI. Preferably, the reagent is a set of primers or a PCR set (a set of primers, DNA polymerase, and 4 nucleoside triphosphates) that hybridizes with the gene or a fragment thereof. The kit also can include other reagents for detecting or measuring the detectable entity and/or a control. Other reagents used for hybridization, prehybridization, DNA extraction, visualization, and the like also can be included.
- The following example further illustrates the invention but, of course, should not be construed as in any way limiting its scope.
- This example demonstrates that genetic markers can be used to identify individuals with a major depressive disorder who develop treatment-emergent suicidal ideation (TESI) when exposed to a selective-serotonin reuptake inhibitor (SSRI), such as citalopram.
- DNA was collected from a clinically-representative cohort of 1938 outpatients with major depressive disorder enrolled in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Outpatients 18-75 years of age with a baseline 17-item Hamilton Depression Rating Scale (see Hamilton et al., J Neurol. Neurosurg. Psychiatry, 23:56-62 (1960); and Hamilton, Br. J. Soc. Clin. Psychol., 6 (4):278-296 (1967)) (HRSD17) score of ≧14 who met the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for non-psychotic major depressive disorder (MDD) were eligible for the trial.
- All participants received initial therapy with citalopram, typically starting at 20 mg/day, with dose increases following recommended procedures (see Trivedi et al., Am. J. Psychiatry, 163 (1):28-40 (2006)). The patients were treated with citalopram under a standard protocol for up to 14 weeks. DNA was extracted from whole blood and genotyped on an Illumina Bead Array platform (see Gunderson et al., Genome Res., 14 (5):870-877 (2004)) for 768 single nucleotide polymorphisms (SNPs) in 68 candidate genes. Genes were selected to sample five broad signaling pathways of potential importance in antidepressant effects: serotonin (20 genes), glutamate (16 genes), dopamine (3 genes), norepinephrine (4 genes), and neurotrophins (4 genes), as well as selected genes in other pathways (21 genes). All probands with TESI and a subset of probands without TESI were also screened with the Illumina 109K Exon-Centric chip, which measures the genotype of a DNA sample at each of 109,000 SNPs in and near most known human genes.
- The 16-item Quick Inventory of Depressive Symptomatology—Self-report (QIDS-SR16) was used as a measure of symptom severity (see Rush et al., Int. J. Methods Psychiatr. Res., 9:45-59 (2000): Rush et al., Biol. Psychiatry, 54 (5): 573-583 (2003); Trivedi et al., Psychol. Med., 34 (1):73-82 (2004); Rush et al., Neuropsychompharmacology, 30 (2):405-416 (2005); and Rush et al., Biol. Psychiatry, 59 (6):493-501 (2006)) and was obtained at baseline and at each bi-weekly clinic visit. TEST was defined by responses to item 12 of the QIDS-SR16 (“Thoughts of death or suicide”). Possible responses include: “I do not think of suicide or death” (=0), “I feel that life is empty or wonder if it's worth living” (=1), “I think of suicide or death several times a week for several minutes” (=2), and “I think of suicide or death several times a day in some detail, or I have made specific plans for suicide, or have actually tried to take my life (=3). Participants who scored “0” on this item before citalopram treatment, but who scored 1, 2, or 3 on the same item at least once while receiving citalopram were defined as TESI cases (n=120). The comparison group (n=1742) consisted of all participants who denied suicidal ideation emerging during treatment. This included participants who denied suicidal ideation at the initial and subsequent visits (n=765), as well as those who admitted to suicidal ideation at the initial visit before commencing treatment, whatever their subsequent report (n=977). Participants missing suicidal ideation data (n=53) were excluded.
- Allele and genotype frequencies were compared between the 120 participants who developed TESI and those who did not develop TESI. Allele-wise tests are most powerful for alleles that confer risk in a co-dominant or dominant fashion, while genotype-wise tests are more powerful when a recessive model applies. Allele-wise comparisons were performed with Cocaphase in the UNPHASED package (see Dudbridge et al., Am. J. Hum. Genet., 75 (3):424-435 (2004)), which estimates a likelihood-based test of association under the null hypothesis of all odds ratios (ORs) being equal to one. Genotype-wise comparisons were carried out using a Pearson Chi-square test on a 2×3 contingency table. Experiment-wise p-values were estimated by permuting case-control labels 10,000 times. The number of p-values less than or equal to the lowest p-value observed in the actual data were tallied. Permutation tests were run separately for autosomal and X-linked markers. Hardy-Weinberg equilibrium for the chosen markers was calculated using PEDSTATS (see Wegginton et al., Bioinformatics, 21(16):3445-3447 (2005)).
- SNPs that passed the initial tests with an experiment-wise p<0.05 were studied further. Tests of association included a logistic regression model calculated with SAS 9.1.3 Enterprise Guide 3.0 (SAS Institute, Cary, N.C.), with a nominal dependent variable for TESI. X-linked markers were separately analyzed in males and females. Single marker tests were carried out under co-dominant, dominant, and recessive models. Models were compared by the Likelihood Ratio Test (LRT). The best-fitting model was used for the multi-marker analyses. The reference model was based on the SNPs with the largest identified ORs in the single marker models. The remaining covariates were added in a step-wise fashion in descending order of OR. The 2 log-likelihood (−2Log L) was used to assess the improvement of fit as each variable was removed from the model. The Hosmer-Lemeshow test was used to test for final model fit.
- Cases and controls were characterized clinically using bivariate methods. Differences between groups were tested by Chi-square statistics for nominal and ordinal variables and by t-statistics for continuous variables.
- Two markers were significantly associated with TESI. A marker in the gene GRIK2 on chromosome 6 (marker 157), which encodes the type 6 glutamate receptor, was associated with TESI in the genotype-wise test (nominal p=2.43×10−5; permutation p<0.003). This marker was not significantly associated in the allele-wise test, but three other markers in this gene produced nominally-significant evidence of allelic association.
- A second marker, in the gene GRIA3 on chromosome X (marker 239), which encodes an AMPA receptor, was associated with TESI in the allele-wise test (nominal p=7.84×10−5; permutation p<0.01). The genotype-wise test of this marker also produced nominally-significant evidence of association in females (p=0.0062), as did allele-wise tests of four nearby markers in this gene.
- Having established experiment-wise significant associations between the two markers and TESI, the impact of non-genetic variables, such as race, on the observed genetic association was investigated. Table 1 includes demographic and clinical data for the 120 participants and the 1742 controls.
-
TABLE 1 Demographic and Clinical Data. Cases (n = 120) Controls (n = 1742) N (%) N (%) df χ2 p Variable Gender (female) 71 (59.2) 1072 (61.5) 1 0.2664 NSa Race 2 1.0563 NS White 91 (75.8) 1382 (79.3) Black 20 (16.7) 262 (15.0) Other 9 (7.5) 98 (5.6) Hispanic (No) 102 (85.0) 1501 (86.2) 1 0.1273 NS Employment 2 1.9630 NS Employed 64 (53.3) 981 (56.3) Retired 6 (5.0) 129 (7.4) Unemployed 50 (41.7) 632 (36.3) Marital status 3 0.6588 NS Married 52 (43.3) 745 (42.8) Divorced 33 (27.5) 435 (25.0) Never Married 31 (25.8) 492 (28.2) Widowed 4 (3.3) 70 (4.0) Clinical Characteristics - Categorical Remission by QIDS-Cb (No) 90 (75.6) 994 (57.2) 1 15.529 <0.0001 Psychomotor Agitation (No) 104 (86.7) 1508 (86.6) 1 0.0010 NS (QIDS-SR16 item 16) Initial Insomnia (No) 104 (86.7) 1530 (87.8) 1 0.1414 NS (QIDS-SR16 item 1) Drug Abuse (No)c 109 (93.2) 1618 (94.0) 1 0.1404 NS Alcohol Abuse (No)c 105 (89.0) 1543 (89.5) 1 0.0254 NS History of Suicide Attempts (No) 101 (84.2) 1481 (85.1) 1 0.0713 NS Medication Tolerabilityd 3 3.1386 NS Intolerant 12 (10.1) 198 (11.4) Probably Intolerant 2 (1.7) 34 (1.9) Probably Tolerant 26 (21.9) 273 (15.7) Tolerant 79 (66.4) 1232 (70.9) Level 1 exit 2 14.834 0.0006 Follow Up 35 (29.2) 805 (46.2) Next Level 75 (62.5) 782 (44.9) Study Exit 10 (8.3) 155 (8.9) Clinical characteristics - Cases (n = 120) Controls (n = 1742) Continuous Mean (SD) Mean (SD) t p Maximum Citalopram Dose (mg/d) 51.75 (13.7) 46.22 (15.3) 3.86 0.0001 Age at Onset of First MDE (yrs.) 24.31 (15.8) 25.89 (15.0) −1.12 NS Age at enrollment (yrs.) 42.26 (13.3) 42.54 (13.4) −0.22 NS aNot significant bDefined as score of 5 or less on the last recorded visit. cBased on self-report responses to the Psychiatric Diagnostic Screening Questionnaire set at 90% specificity (see Rush et al., J. Affect. Disord., 87(1): 43-55 (2005)). dAs defined by the algorithm detailed in McMahon et al. (Am. J. Hum. Genet., 78(5): 804-814 (2006)). - The best-fitting model was achieved with a combination of both markers, maximum citalopram dose, and remission by the 16-Item Quick Inventory of Depressive Symptomatology (QIDS)—Clinician Rating (QIDS-C). Race was not a significant covariate in this model. Adjusted ORs were very close to those in the unadjusted models. The Hosmer-Lemeshow test was non-significant for both genders, indicating a good model fit.
- Tables 2 and 3 demonstrate logistic regression models with stepwise selection for the two markers, wherein race was forced into each model.
-
TABLE 2 Logistic Regression Model for Females (n = 70 cases, 1067 controls). Step Model variables −2Log L LR χ2 df p-value 1 marker 157 and race 519.6 6.3 3 0.0982 2 marker 157, remission, race 512.2 13.7 4 0.0084 3 marker 157, marker 239, 505.2 20.7 5 0.0009 remission, race wherein LR = likelihood ratio, df = degrees of freedom. The c index for this model is 0.64. -
TABLE 3 Logistic Regression Model for Males (n = 49 cases, 670 controls). Step Model variables −2Log L LR χ2 df p-value 1 marker 157 and race 346.5 11.3 3 0.01 2 marker 157, maximum 334.1 23.8 4 <.0001 citalopram dose, race 3 marker 157, maximum 327.8 30.1 5 <.0001 citalopram dose, marker 239, race 4 marker 157, marker 323.0 34.8 6 <.0001 239, maximum citalopram dose, remission, race The c index for this model is 0.73. - The clinical parameters for markers 157 and 239 are reported in Table 4. The high-risk genotype of marker 157 correlates with a SNP in intron 1 of GRIK2 (e.g., SEQ ID NO: 1). The high-risk alleles of marker 239 contain a SNP in intron 3 of GRIA3 (e.g., SEQ ID NOs: 2 and 3). Of the six combinations of high-risk alleles and genotypes tested, the highest OR was observed in patients carrying both the high-risk alleles of marker 239 and the high-risk genotype of marker 157 (OR=14.98, 95% Confidence Interval (CI)=3.7, 60.674). Although only 8 patients carried it, this particular combination of alleles had 99.8% specificity for TESI. The most sensitive test (57%) required the presence of one or more high-risk alleles of marker 239 only. The combined impact of both markers on TESI risk appears to be at least additive, but sample size precludes any precise estimates of the mode of interaction.
-
TABLE 4 Clinical parameters for Markers 157 and 239. Positive Negative 95% Predictive Predictive Prevalence Model OR CI Sensitivity Specificity Value Value Ratio (1) marker 8.23 3.224, 21.057 0.06 0.993 0.35 0.94 5.71 157, high-risk genotype (2) marker 1.94 1.33, 2.82 0.57 0.59 0.09 0.95 1.85 239, ≧ one high- risk allele (3) marker 2.19 1.45, 3.32 0.29 0.84 0.11 0.95 2.06 239, two high- risk alleles Both (1) and 8.55 2.47, 29.62 0.03 0.996 0.36 0.94 5.82 (2) Either (1) or 2.38 1.59, 3.57 0.32 0.84 0.12 0.95 2.22 (3) Both (1) and 14.9 3.70, 60.67 0.033 0.998 0.50 0.94 7.99 (3) - The identified markers, taken together, predict TESI in this sample with high specificity, but only moderate sensitivity. This is not surprising given the relatively small number of genes tested and the likely contribution of non-genetic factors to TESI risk. Nevertheless, the findings have several direct clinical implications.
- These markers can help identify patients at high risk for TESI. Such patients will benefit from closer monitoring, alternative treatments, and/or specialty care. Such testing can allay the concern that has led regulatory agencies to issue warnings that contribute to a decrease in antidepressant prescriptions for patients who could benefit from them. Rather than broad warnings that can inappropriately affect antidepressant prescribing practices, identification of these markers indicates that narrower warnings could be appropriate that better capture the heterogeneous nature of TESI risk in those patients treated with antidepressants. These findings suggest that at least some of that heterogeneity has a genetic basis.
- Several other markers were identified that correlate with an increased risk of TESI. These markers were identified in the following genes: GRIN2A, NTRK2, HTR3B, GRIA1, and PAPLN. SNPs in intron 3 of GRIN2A (e.g., SEQ ID NO: 4), intron 14 of NTRK2 (e.g., SEQ ID NO: 5), intron 16 of HTR3B (e.g., SEQ ID NO: 6), intron 5 of GRIA1 (SEQ ID NO: 7), and intron 13 of PAPLN (e.g., SEQ ID NOs: 8 or 9) were associated with increased risk of TESI in those treated with citalopram.
- In particular, markers in PAPLN (marker rs11628713) and IL28RA (marker rs10903034) were significant at the p=0.01 and p=0.06 levels, respectively, in an evaluation of 90 TESI cases and 90 matched controls.
- All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
- The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
- Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
Claims (25)
1. A method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising:
(a) obtaining a sample of genetic material from the patients, and
(b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation,
wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof.
2. The method of claim 1 , wherein assaying comprises detecting the polymorphism by allele specific hybridization, allele specific oligonucleotide ligation, primer extension, minisequencing, mass spectroscopy, heteroduplex analysis, single strand conformational polymorphism (SSCP), denaturing gradient gel electrophoresis (DGGE), oligonucleotide microarray analysis, temperature gradient gel electrophoresis (TGGE), and combinations thereof.
3. The method of claim 1 , wherein the gene is GRIK2.
4. The method of claim 3 , wherein the polymorphism is within intron 1 of GRIK2.
5. The method of claim 4 , wherein intron 1 of GRIK2 comprises SEQ ID NO: 1.
6. The method of claim 1 , wherein the gene is GRIA3.
7. The method of claim 6 , wherein the polymorphism is within intron 3 of GRIA3.
8. The method of claim 7 , wherein intron 3 of GRIA3 comprises SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 13.
9. The method of claim 1 , further comprising assaying for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamate receptor, ionotropic, N-methyl D-aspartate (GRIN) 2A; neurotrophic tyrosine receptor kinase (NTRK) 2; 5-hydroxytryptamine (serotonin) receptor (HTR) 3B, GRIA1; papilin (PAPLN); interleukin 28 receptor alpha (IL28RA); and combinations thereof.
10. The method of claim 9 , wherein assaying for the presence of the genotype comprises detecting the presence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO 12, or combinations thereof.
11. A method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising:
(a) obtaining a sample of genetic material from the patients, and
(b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation,
wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamate receptor, ionotropic, N-methyl D-aspartate (GRIN) 2A; neurotrophic tyrosine receptor kinase (NTRK) 2; 5-hydroxytryptamine (serotonin) receptor (HTR) 3B, GRIA1; papilin (PAPLN); interleukin 28 receptor alpha (IL28RA); and combinations thereof.
12. The method of claim 11 , wherein assaying comprises detecting the polymorphism by allele specific hybridization, allele specific oligonucleotide ligation, primer extension, minisequencing, mass spectroscopy, heteroduplex analysis, single strand conformational polymorphism (SSCP), denaturing gradient gel electrophoresis (DGGE), oligonucleotide microarray analysis, temperature gradient gel electrophoresis (TGGE), and combinations thereof.
13. The method of claim 11 , wherein the gene is GRIN2A.
14. The method of claim 13 , wherein the polymorphism is within intron 3 of GRIN2A.
15. The method of claim 11 , wherein the gene is NTRK2.
16. The method of claim 15 , wherein the polymorphism is within intron 14 of NTRK2.
17. The method of claim 11 , wherein the gene is HTR3B.
18. The method of claim 17 , wherein the polymorphism is within intron 6 of HTR3B.
19. The method of claim 11 , wherein the gene is GRIA1.
20. The method of claim 19 , wherein the polymorphism is within intron 5 of GRIA1.
21. The method of claim 11 , wherein the gene is PAPLN.
22. The method of claim 21 , wherein the polymorphism is within intron 13 of PAPLN.
23. The method of claim 11 , wherein the gene is IL28RA.
24. The method of claim 23 , wherein the polymorphism is within exon 7 of IL28RA.
25. The method of claim 23 , wherein the polymorphism is within intron 4 of IL28RA.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/015,068 US20110118133A1 (en) | 2006-10-27 | 2011-01-27 | Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85497806P | 2006-10-27 | 2006-10-27 | |
US11/925,334 US7906283B2 (en) | 2006-10-27 | 2007-10-26 | Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication |
US13/015,068 US20110118133A1 (en) | 2006-10-27 | 2011-01-27 | Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/925,334 Continuation US7906283B2 (en) | 2006-10-27 | 2007-10-26 | Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110118133A1 true US20110118133A1 (en) | 2011-05-19 |
Family
ID=39276298
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/925,334 Expired - Fee Related US7906283B2 (en) | 2006-10-27 | 2007-10-26 | Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication |
US13/015,068 Abandoned US20110118133A1 (en) | 2006-10-27 | 2011-01-27 | Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/925,334 Expired - Fee Related US7906283B2 (en) | 2006-10-27 | 2007-10-26 | Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication |
Country Status (5)
Country | Link |
---|---|
US (2) | US7906283B2 (en) |
EP (1) | EP2087136A2 (en) |
JP (1) | JP2010508029A (en) |
CA (1) | CA2667812A1 (en) |
WO (1) | WO2008052167A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2736936A1 (en) | 2008-09-18 | 2010-03-25 | Andreas Menke | Means and methods for diagnosing predisposition for treatment emergent suicidal ideation (tesi) |
EP2166112B1 (en) | 2008-09-18 | 2013-06-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for diagnosing predisposition for treatment emergent suicidal ideation |
WO2015006645A1 (en) | 2013-07-11 | 2015-01-15 | The Johns Hopkins University | A dna methylation and genotype specific biomarker of suicide attempt and/or suicide ideation |
WO2016168685A1 (en) * | 2015-04-17 | 2016-10-20 | Mayo Foundation For Medical Education And Research | Modulating the aryl hydrocarbon receptor system to treat major depressive disorder |
CA2891830A1 (en) * | 2015-05-15 | 2016-11-15 | Centre For Addiction And Mental Health | Genetic markers for suicide risk and related methods |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040265825A1 (en) * | 2001-01-19 | 2004-12-30 | Boris Tartakovsky | Methods and compositions for diagnosing and treating a subject having depression |
US20050069936A1 (en) * | 2003-09-26 | 2005-03-31 | Cornelius Diamond | Diagnostic markers of depression treatment and methods of use thereof |
US20060160119A1 (en) * | 2005-01-14 | 2006-07-20 | Barbara Turner | Genetic screening for improving treatment of patients diagnosed with depression |
US7083921B2 (en) * | 2001-08-29 | 2006-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method to determine the risk for side effects of an SSRI treatment in a person |
US20070003931A1 (en) * | 2003-02-20 | 2007-01-04 | Mrazek David A | Methods for selecting medications |
US20080299135A1 (en) * | 2003-05-15 | 2008-12-04 | The University Of Chicago | Methods and compositions for nerve regeneration |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080299125A1 (en) | 2006-06-05 | 2008-12-04 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
-
2007
- 2007-10-26 WO PCT/US2007/082683 patent/WO2008052167A2/en active Application Filing
- 2007-10-26 US US11/925,334 patent/US7906283B2/en not_active Expired - Fee Related
- 2007-10-26 JP JP2009534893A patent/JP2010508029A/en not_active Withdrawn
- 2007-10-26 CA CA 2667812 patent/CA2667812A1/en not_active Abandoned
- 2007-10-26 EP EP07868595A patent/EP2087136A2/en not_active Withdrawn
-
2011
- 2011-01-27 US US13/015,068 patent/US20110118133A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040265825A1 (en) * | 2001-01-19 | 2004-12-30 | Boris Tartakovsky | Methods and compositions for diagnosing and treating a subject having depression |
US7083921B2 (en) * | 2001-08-29 | 2006-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method to determine the risk for side effects of an SSRI treatment in a person |
US20070003931A1 (en) * | 2003-02-20 | 2007-01-04 | Mrazek David A | Methods for selecting medications |
US20080299135A1 (en) * | 2003-05-15 | 2008-12-04 | The University Of Chicago | Methods and compositions for nerve regeneration |
US20050069936A1 (en) * | 2003-09-26 | 2005-03-31 | Cornelius Diamond | Diagnostic markers of depression treatment and methods of use thereof |
US20060160119A1 (en) * | 2005-01-14 | 2006-07-20 | Barbara Turner | Genetic screening for improving treatment of patients diagnosed with depression |
Non-Patent Citations (5)
Title |
---|
Cotton, R.G.H.. Mutation Research. 1993. 285: 125-144. * |
Fan et al. Cold Spring Harb Symp Quant Biol. 2003. 68: 69-78 * |
GeneCard for the GRIA3 gene available via url: , printed 13 December 2011. * |
GeneCard for the GRIK2 gene available via url: , printed 12 December 2011. * |
Gunderson et al. Genome Research. 2004. 14: 870-877 * |
Also Published As
Publication number | Publication date |
---|---|
US7906283B2 (en) | 2011-03-15 |
JP2010508029A (en) | 2010-03-18 |
WO2008052167A2 (en) | 2008-05-02 |
EP2087136A2 (en) | 2009-08-12 |
WO2008052167A3 (en) | 2008-11-13 |
CA2667812A1 (en) | 2008-05-02 |
US20080102467A1 (en) | 2008-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Addington et al. | Polymorphisms in the 13q33. 2 gene G72/G30 are associated with childhood-onset schizophrenia and psychosis not otherwise specified | |
US7795033B2 (en) | Methods to predict the outcome of treatment with antidepressant medication | |
Uhart et al. | GABRA2 markers moderate the subjective effects of alcohol | |
Tzvetkov et al. | Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment | |
US10072289B2 (en) | Genetic addiction risk analysis for RDS severity index | |
US20150278438A1 (en) | Genetic predictors of response to treatment with crhr1 antagonists | |
Gamero-Villarroel et al. | BDNF genetic variability modulates psychopathological symptoms in patients with eating disorders | |
Chen et al. | Mitochondrial ND5 T12338C, tRNACys T5802C, and tRNAThr G15927A variants may have a modifying role in the phenotypic manifestation of deafness‐associated 12S rRNA A1555G mutation in three Han Chinese pedigrees | |
Barral et al. | Linkage analyses in Caribbean Hispanic families identify novel loci associated with familial late-onset Alzheimer's disease | |
US20110118133A1 (en) | Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication | |
US20110086777A1 (en) | Method for autism prediction | |
US20060286594A1 (en) | Detection of antidepressant induced mania | |
US20110091899A1 (en) | Combination of risk alleles associated with autism | |
US20070065821A1 (en) | Methods for the prediction of suicidality during treatment | |
US20150315651A1 (en) | Methods and kits for determining a placebo profile in subjects for clinical trials and for treatment of patients | |
AU2005250142B2 (en) | Biomarkers for the prediction of responsiveness to clozapine treatment | |
US20130317006A1 (en) | Use of polymorphisms for identifying individuals at risk of developing autism | |
Seal et al. | Segmental uniparental isodisomy on 5q32-qter in a patient with childhood-onset schizophrenia | |
Amstadter et al. | Selected summaries from the XVII World Congress of Psychiatric Genetics, San Diego, California, USA, 4–8 November 2009 | |
EP3045541A1 (en) | Test method for evaluating the risk of anti-thyroid drug-induced agranulocytosis, and evaluation kit | |
Cheah | Understanding the risk and functional importance of schizophrenia genetic factors | |
Cavalleri | Haplotype mapping in epilepsy genetics and pharmacogenetics | |
WO2011045402A1 (en) | Autism-associated functional polymorphisms in slc25a12 gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |